Neuroblastoma charities unite to beat cancer

Press Release

Monday, 14 May 2018

Two leading Neuroblastoma research funding charities have today announced that they will be uniting to beat childhood cancer. Neuroblastoma UK (NBUK) and Smile with Siddy merger will combine resources to drive forward research into Neuroblastoma, the second most common solid tumour in Childhood.

In announcing the merger Tony Heddon, Chair of Neuroblastoma UK (NBUK) said:

“NBUK and Smile with Siddy have worked successfully together in recent years in supporting research to find a cure and relieve children suffering from Neuroblastoma. Combining our respective strengths will enable us to drive forward research into a disease that is responsible for 1 in 6 of all children’s cancer deaths.”

Flora Cahill, Chair of Smile with Siddy said “ Smile with Siddy and NBUK share the same belief that the only way more children will survive this horrible disease is through research. Through this integration Smile with Siddy will continue to operate as a fund within NBUK, benefitting from their expertise in supporting ground breaking research, while we focus our energies on fund raising and spreading awareness.”

Notes for editors:

  • NBUK, founded in 1982, is a leading funder of research into neuroblastoma and has funded £5 million of research in the UK.

  • Smile with Siddy started in 2013 in honour of Siddy Cahill who sadly died of neuroblastoma, aged 17 months. They have raised in excess of £150,000 to fund research.

  • Neuroblastoma is an extremely aggressive cancer that mainly affects children under the age of 5 years

  • Neuroblastoma is the second most common solid tumour in childhood.

  • Neuroblastoma originates from the cells involved in the development of a baby’s nervous tissue.

Media enquiries should be directed to media@neuroblastoma.org.uk

For further information about Neuroblastoma UKs work please call 020 8940 4353 or visit www.neuroblastoma.org.uk

Previous
Previous

Update - NICE decision re Dinutuximab beta

Next
Next

NBUK statement on NICE decision not to fund Dinutuximab beta for children